Abstract
In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
Keywords: Network pharmacology, drug attrition, systems biology, network medicine
Current Drug Discovery Technologies
Title:Network Pharmacology: Reigning in Drug Attrition?
Volume: 10 Issue: 2
Author(s): Osama M. Alian, Minjel Shah, Momin Mohammad and Ramzi M. Mohammad
Affiliation:
Keywords: Network pharmacology, drug attrition, systems biology, network medicine
Abstract: In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
Export Options
About this article
Cite this article as:
M. Alian Osama, Shah Minjel, Mohammad Momin and M. Mohammad Ramzi, Network Pharmacology: Reigning in Drug Attrition?, Current Drug Discovery Technologies 2013; 10 (2) . https://dx.doi.org/10.2174/1570163811310020008
DOI https://dx.doi.org/10.2174/1570163811310020008 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study
Current Medicinal Chemistry - Anti-Cancer Agents Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Hybrid Imidazole-Pyridine Derivatives: An Approach to Novel Anticancer DNA Intercalators
Current Medicinal Chemistry ABC Transporters, Bile Acids, and Inflammatory Stress in Liver Cancer
Current Pharmaceutical Biotechnology Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects
Current Bioinformatics Life and Death of Nerve Cells: Therapeutic Cytokine Signaling Pathways
Current Signal Transduction Therapy Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Current Drug Targets Direct Selection of cDNAs from Filamentous Phage Surface Display Libraries: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry The Yin and Yang of CD4+ Regulatory T Cells in Autoimmunity and Cancer
Current Medicinal Chemistry Cancer Nanotechnology: Recent Trends and Developments in Strategies for Targeting Cancer Cells to Improve Cancer Imaging and Treatment
Current Drug Metabolism Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment
Current Pharmaceutical Design Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Genomic Instability and Cancer
Current Molecular Medicine Anesthetic and Adjunctive Drugs for Fast-Track Surgery
Current Drug Targets Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets